 |
Previous Article | Next Article 
The Journal of Neuroscience, September 1, 2001, 21(17):6475-6479
Neuroprotection by 9-Tetrahydrocannabinol, the
Main Active Compound in Marijuana, against
Ouabain-Induced In Vivo Excitotoxicity
M.
van der Stelt1,
W.
B.
Veldhuis2, 3,
P. R.
Bär3,
G. A.
Veldink1,
J. F. G.
Vliegenthart1, and
K.
Nicolay2
1 Department of Bio-Organic Chemistry, Bijvoet Center
for Biomolecular Research, 3584 CH, Utrecht University, Utrecht, The
Netherlands, 2 Department of Experimental In Vivo
NMR, Image Sciences Institute, 3584 CJ, Utrecht, University
Medical Center Utrecht, The Netherlands, and 3 Department
of Experimental Neurology, University Medical Center Utrecht, 3584 CX,
Utrecht, The Netherlands
Excitotoxicity is a paradigm used to explain the biochemical events
in both acute neuronal damage and in slowly progressive, neurodegenerative diseases. Here, we show in a longitudinal magnetic resonance imaging study that
9-tetrahydrocannabinol ( 9-THC), the
main active compound in marijuana, reduces neuronal injury in neonatal
rats injected intracerebrally with the
Na+/K+-ATPase inhibitor ouabain
to elicit excitotoxicity. In the acute phase 9-THC
reduced the volume of cytotoxic edema by 22%. After 7 d, 36%
less neuronal damage was observed in treated rats compared with control
animals. Coadministration of the CB1 cannabinoid receptor
antagonist SR141716 prevented the neuroprotective actions of
9-THC, indicating that 9-THC afforded
protection to neurons via the CB1 receptor. In
9-THC-treated rats the volume of astrogliotic tissue was
36% smaller. The CB1 receptor antagonist did not block
this effect. These results provide evidence that the cannabinoid system
can serve to protect the brain against neurodegeneration.
Key words:
anandamide; astrogliosis; cannabinoid; excitotoxicity; magnetic resonance imaging; neonatal rat; neuroprotection; ouabain; THC
Copyright © 2001 Society for Neuroscience 0270-6474/01/21176475-05$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
A. Ludanyi, L. Eross, S. Czirjak, J. Vajda, P. Halasz, M. Watanabe, M. Palkovits, Z. Magloczky, T. F. Freund, and I. Katona
Downregulation of the CB1 Cannabinoid Receptor and Related Molecular Elements of the Endocannabinoid System in Epileptic Human Hippocampus
J. Neurosci.,
March 19, 2008;
28(12):
2976 - 2990.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Pacher, S. Batkai, and G. Kunos
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev.,
September 1, 2006;
58(3):
389 - 462.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. G. Ramirez, C. Blazquez, T. G. del Pulgar, M. Guzman, and M. L. de Ceballos
Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation
J. Neurosci.,
February 23, 2005;
25(8):
1904 - 1913.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Schenning, C. M. van Tiel, D. van Manen, J. C. Stam, B. M. Gadella, K. W. A. Wirtz, and G. T. Snoek
Phosphatidylinositol transfer protein {alpha} regulates growth and apoptosis of NIH3T3 cells: involvement of a cannabinoid 1-like receptor
J. Lipid Res.,
August 1, 2004;
45(8):
1555 - 1564.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Geller, L. Loftis, and D. S. Brink
Cerebellar Infarction in Adolescent Males Associated With Acute Marijuana Use
Pediatrics,
April 1, 2004;
113(4):
e365 - e370.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Bjork, S. J. Grant, and D. W. Hommer
Cross-Sectional Volumetric Analysis of Brain Atrophy in Alcohol Dependence: Effects of Drinking History and Comorbid Substance Use Disorder
Am J Psychiatry,
November 1, 2003;
160(11):
2038 - 2045.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. El-Remessy, I. E. Khalil, S. Matragoon, G. Abou-Mohamed, N.-J. Tsai, P. Roon, R. B. Caldwell, R. W. Caldwell, K. Green, and G. I. Liou
Neuroprotective Effect of(-){Delta}9-Tetrahydrocannabinol and Cannabidiol in N-Methyl-D-Aspartate-Induced Retinal Neurotoxicity: Involvement of Peroxynitrite
Am. J. Pathol.,
November 1, 2003;
163(5):
1997 - 2008.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. B. Veldhuis, M. van der Stelt, M. W. Wadman, G. van Zadelhoff, M. Maccarrone, F. Fezza, G. A. Veldink, J. F. G. Vliegenthart, P. R. Bar, K. Nicolay, et al.
Neuroprotection by the Endogenous Cannabinoid Anandamide and Arvanil against In Vivo Excitotoxicity in the Rat: Role of Vanilloid Receptors and Lipoxygenases
J. Neurosci.,
May 15, 2003;
23(10):
4127 - 4133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Gomez del Pulgar, M. L. de Ceballos, M. Guzman, and G. Velasco
Cannabinoids Protect Astrocytes from Ceramide-induced Apoptosis through the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway
J. Biol. Chem.,
September 20, 2002;
277(39):
36527 - 36533.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Mechoulam, M. Spatz, and E. Shohami
Endocannabinoids and Neuroprotection
Sci. Signal.,
April 23, 2002;
2002(129):
re5 - re5.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. van der Stelt, W. B. Veldhuis, G. W. van Haaften, F. Fezza, T. Bisogno, P. R. Bar, G. A. Veldink, J. F. G. Vliegenthart, V. Di Marzo, and K. Nicolay
Exogenous Anandamide Protects Rat Brain against Acute Neuronal Injury In Vivo
J. Neurosci.,
November 15, 2001;
21(22):
8765 - 8771.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|